Deucravacitinib
| Catalog Number | Pack Size | List Price* | Promo Price* | Quantity | |
|---|---|---|---|---|---|
| HY-117287-2MG | 2 mg | 143,00 | 88,70 | Add | |
| HY-117287-5MG | 5 mg | 265,00 | 164,30 | Add | |
| HY-117287-1ML | 10mM/1mL | 289,00 | 179,20 | Add | |
| HY-117287-10MG | 10 mg | 473,00 | 293,30 | Add | |
| HY-117287-25MG | 25 mg | 730,00 | 452,60 | Add | |
| HY-117287-50MG | 50 mg | 1'118,00 | 693,20 | Add | |
| HY-117287-100MG | 100 mg | 1'570,00 | 973,40 | Add | |
| HY-117287-200MG | 200 mg | 2'035,00 | 1'261,70 | Add | |
| HY-117287-500MG | 500 mg | 3'119,00 | 1'933,80 | Add | |
| HY-117287-1G | 1 g | 4'049,00 | 2'510,40 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Promotion runs until 31.12.2026Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
BMS-986165
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis[1][2].
| Category | Biochemicals |
| Supplier | MedChem Express |
| Application | Isotope-labeled compound |
| Regulatory Status | RUO |
| Research Field | Inflammation/Immunology |
| Format | Solubility: DMSO : 33.33 mg/mL (ultrasonic) |
| Grade | Clinical information: Launched |
| Purity | 99.93% |
| Molecular Formula | C20H19D3N8O3 |
| Molecular Weight | 425.46 |
| CAS-Number | 1609392-27-9 |
| Storage Conditions | -20°C, 3 years (Powder) |
| Disclaimer | Deuterated products takes approx 1 week longer delivery time |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Blue Ice |
| Material Safety Data Sheet | Download PDF |
